Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer

Clinical Cancer Research

Volumn 23, Issue 19, 2017, Pages 5757-5768

  Dolan, M Eileen ^a   Charif, Omar El ^a   Wheeler, Heather E ^b   Gamazon, Eric R ^c   Ardeshir Rouhani fard, Shirin ^d   Monahan, Patrick ^d   Feldman, Darren R ^e   Hamilton, Robert J ^f   Vaughn, David J ^g   Beard, Clair J ^h   Fung, Chunkit ⁱ   Kim, Jeri ^j   Fossa, Sophie D ^k   Hertz, Daniel L ^l   Mushiroda, Taisei ^m   Kubo, Michiaki ^m   Einhorn, Lawrence H ^d   Cox, Nancy J ^c   Travis, Lois B ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l UNIVERSITY OF MICHIGAN   (United States)

^m Institute of Physical and Chemical Research   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CELL CYCLE PROTEIN; CREPT PROTEIN, HUMAN; TUMOR PROTEIN;

ADULT; ADULT DISEASE; AGE; ALCOHOL ABUSE; ARTICLE; BODY MASS; CANCER CHEMOTHERAPY; CANCER SURVIVOR; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HEALTH STATUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDN GENE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; RPRD1B GENE; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TESTIS CANCER; THEM5 GENE; ADOLESCENT; AGED; CHEMICALLY INDUCED; COMPLICATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MIDDLE AGED; ONSET AGE; PATHOLOGY; TESTIS TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; AGED; CANCER SURVIVORS; CELL CYCLE PROTEINS; CISPLATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PERIPHERAL NERVOUS SYSTEM DISEASES; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TESTICULAR NEOPLASMS;

EID: 85032369714     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-3224     Document Type: Article

References (53)

1. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 2012;82:51-77.
2. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 2016; 140:176-83.
3. Avan A, Postma TJ, Ceresa C, Avan A, Cavaletti G, Giovannetti E, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist 2015;20:411-32.
4. Hershman DL, Till C, Wright JD, Awad D, Ramsey SD, Barlow WE, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol 2016;34:3014-22.
5. Kawakami K, Tunoda T, Takiguchi T, Shibata K, Ohtani T, Kizu J, et al. Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer. Oncol Res 2012;20:179-85.
6. Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, et al. Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 2013;21:1313-9.
7. Uwah AN, Ackler J, Leighton JC Jr, Pomerantz S, Tester W. The effect of diabetes on oxaliplatin-induced peripheral neuropathy. Clin Colorectal Cancer 2012;11:275-9.
8. Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, et al. Genome-wide association studies for taxane-induced peripheral neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 2015;21: 5082-91.
9. Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010;116:2322-31.
10. Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes JM, et al. Chemotherapy-induced peripheral neuropathy after neoadjuvant or adjuvant treatment of breast cancer: a prospective cohort study. Support Care Cancer 2016;24:1571-81.
11. Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK. Docetaxelinduced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Acta Oncol 2015;54:530-7.
12. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapyinduced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:1941-67.
13. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 2002;99:4592-5.
14. Travis LB, Foss a SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014;106. pii: dju044. doi:10.1093/jnci/dju044.
15. Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, et al. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population- based study. Gynecol Oncol 2009;113:264-9.
16. Khrunin AV, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010;10:54-61.
17. Khrunin AV, Khokhrin DV, Moisseev AA, Gorbunova VA, Limborska SA. Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics 2014;15:329-37.
18. Oldenburg J, Kraggerud SM, Brydoy M, Cvancarova M, Lothe RA, Fossa SD. Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 2007;5:70.
19. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, et al. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013;24:454-62.
20. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. Eur J Cancer 2005;41:1135-9.
21. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297-334.
22. Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, et al. North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 2014;120:1890-7.
23. Gaist D, Jeppesen U, An dersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002;58:1333-7.
24. Taylor HL, Jacobs DR Jr, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis 1978;31:741-55.
25. Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, et al. Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 1996;7:81-6.
26. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Mapes B, et al. Variantsin WFS1 and other Mendelian deafness genes are associated with cisplatin-associated ototoxicity. Clin Cancer Research. In press, Dec 30, 2016. doi:10.1158/1078-0432 [Epub ahead of print].
27. Patterson N, Price AL, Reich D. Population structure and eigenanalysis. PLoS Genet 2006;2:e190.
28. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44:955-9.
29. Aschard H, Vilhjalmsson BJ, Joshi AD, Price AL, Kraft P. Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. Am J Hum Genet 2015;96:329-39.
30. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 2011;88:76-82.
31. Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ, et al. A gene-based associationmethod formapping traits using reference transcriptome data. Nat Genet 2015;47:1091-8.
32. Battle A, Mostafavi S, Zhu X, Potash JB, Weissman MM, McCormick C, et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res 2014;24:14-24.
33. Consortium GT. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45:580-5.
34. Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown- Gentry K, et al. PheWAS: demonstrating the feasibility of a phenomewide scan to discover gene-disease associations. Bioinformatics 2010; 26:1205-10.
35. Denny JC, Bastarache L, RitchieMD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Biotechnol 2013;31:1102-10.
36. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, et al. Pharmacogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 2016;22:4890-900.
37. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 2016;34:2712-20.
38. Goekkurt E, Al-Batran SE, Hartmann JT, Mogck U, Schuch G, Kramer M, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 2009;27:2863-73.
39. Lamba JK, Fridley BL, Ghosh TM, Yu Q, Mehta G, Gupta P. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 2014;15:1565-74.
40. Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treatedwith adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011;125:767-74.
41. Wolf SL, Barton DL, Qin R, Wos EJ, Sloan JA, Liu H, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 2012;20:625-32.
42. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 2010;107:9287-92.
43. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Traitassociated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 2010;6:e1000888.
44. Ni Z, Olsen JB, Guo X, Zhong G, Ruan ED, Marcon E, et al. Control of the RNA polymerase II phosphorylation state in promoter regions by CTD interaction domain-containing proteins RPRD1A and RPRD1B. Transcription 2011;2:237-42.
45. Morales JC, Richard P, Rommel A, Fattah FJ, Motea EA, Patidar PL, et al. Kub5-Hera, the human Rtt103 homolog, plays dual functional roles in transcription termination and DNA repair. Nucleic Acids Res 2014;42: 4996-5006.
46. Patidar PL, Motea EA, Fattah FJ, Zhou Y, Morales JC, Xie Y, et al. The Kub5- Hera/RPRD1B interactome: a novel role in preserving genetic stability by regulating DNA mismatch repair. Nucleic Acids Res 2016;44:1718-31.
47. Sawant A, Kothandapani A, Zhitkovich A, Sobol RW, Patrick SM. Role of mismatch repair proteins in the processing of cisplatin interstrand crosslinks. DNA Repair (Amst) 2015;35:126-36.
48. Zhang Y, Liu C, Duan X, Ren F, Li S, Jin Z, et al. CREPT/RPRD1B, a recently identified novel protein highly expressed in tumors, enhances the betacatenin. TCF4 transcriptional activity in response to Wnt signaling. J Biol Chem 2014;289:22589-99.
49. Ille F, Sommer L. Wnt signaling: multiple functions in neural development. Cell Mol Life Sci 2005;62:1100-8.
50. Simonetti M, Agarwal N, Stosser S, Bali KK, Karaulanov E, Kamble R, et al. Wnt-Fzd signaling sensitizes peripheral sensory neurons via distinct noncanonical pathways. Neuron 2014;83:104-21.
51. Mellion M, Gilchrist JM, de la Monte S. Alcohol-related per ipheral neuropathy: nutritional, toxic, or both? Muscle Nerve 2011;43:309-16.
52. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 2011;7:208-20.
53. Grov EK, Fossa SD, Bremnes RM, Dahl O, Klepp O, Wist E, et al. The personality trait of neuroticism is strongly associated with longterm morbidity in testicular cancer survivors. Acta Oncol 2009;48: 842-9.